258 related articles for article (PubMed ID: 34465478)
21. Occult and subsequent cancer incidence following risk-reducing surgery in BRCA mutation carriers.
Zakhour M; Danovitch Y; Lester J; Rimel BJ; Walsh CS; Li AJ; Karlan BY; Cass I
Gynecol Oncol; 2016 Nov; 143(2):231-235. PubMed ID: 27623252
[TBL] [Abstract][Full Text] [Related]
22. Incidence and Characteristics of Unsuspected Neoplasia Discovered in High-Risk Women Undergoing Risk Reductive Bilateral Salpingooophorectomy.
Poon C; Hyde S; Grant P; Newman M; Ireland Jenkin K
Int J Gynecol Cancer; 2016 Oct; 26(8):1415-20. PubMed ID: 27488216
[TBL] [Abstract][Full Text] [Related]
23. Transitional cell metaplasia of fallopian tube fimbriae: a potential mimic of early tubal carcinoma in risk reduction salpingo-oophorectomies from women With BRCA mutations.
Rabban JT; Crawford B; Chen LM; Powell CB; Zaloudek CJ
Am J Surg Pathol; 2009 Jan; 33(1):111-9. PubMed ID: 18830124
[TBL] [Abstract][Full Text] [Related]
24. Risk of Peritoneal Carcinomatosis After Risk-Reducing Salpingo-Oophorectomy: A Systematic Review and Individual Patient Data Meta-Analysis.
Steenbeek MP; van Bommel MHD; Bulten J; Hulsmann JA; Bogaerts J; Garcia C; Cun HT; Lu KH; van Beekhuizen HJ; Minig L; Gaarenstroom KN; Nobbenhuis M; Krajc M; Rudaitis V; Norquist BM; Swisher EM; Mourits MJE; Massuger LFAG; Hoogerbrugge N; Hermens RPMG; IntHout J; de Hullu JA
J Clin Oncol; 2022 Jun; 40(17):1879-1891. PubMed ID: 35302882
[TBL] [Abstract][Full Text] [Related]
25. Risk reducing surgery with peritoneal staging in BRCA1-2 mutation carriers. A prospective study.
Marchetti C; Arcieri M; Vertechy L; Ergasti R; Russo G; Zannoni GF; Minucci A; Ercoli A; Scambia G; Fagotti A
Eur J Surg Oncol; 2022 Dec; 48(12):2539-2544. PubMed ID: 35871032
[TBL] [Abstract][Full Text] [Related]
26. Serous tubal intraepithelial carcinoma localizes to the tubal-peritoneal junction: a pivotal clue to the site of origin of extrauterine high-grade serous carcinoma (ovarian cancer).
Seidman JD
Int J Gynecol Pathol; 2015 Mar; 34(2):112-20. PubMed ID: 25675178
[TBL] [Abstract][Full Text] [Related]
27. Serous tubal intraepithelial carcinoma: its potential role in primary peritoneal serous carcinoma and serous cancer prevention.
Carlson JW; Miron A; Jarboe EA; Parast MM; Hirsch MS; Lee Y; Muto MG; Kindelberger D; Crum CP
J Clin Oncol; 2008 Sep; 26(25):4160-5. PubMed ID: 18757330
[TBL] [Abstract][Full Text] [Related]
28. p53 signature and serous tubal in-situ carcinoma in cases of primary tubal and peritoneal carcinomas and serous borderline tumors of the ovary.
Leonhardt K; Einenkel J; Sohr S; Engeland K; Horn LC
Int J Gynecol Pathol; 2011 Sep; 30(5):417-24. PubMed ID: 21804388
[TBL] [Abstract][Full Text] [Related]
29. Risk-reducing salpingo-oophorectomy among Chinese women at increased risk of breast and ovarian cancer.
Feng Z; Zuo K; Ju X; Chen X; Yang W; Wen H; Yu L; Wu X
J Ovarian Res; 2023 Jun; 16(1):125. PubMed ID: 37386498
[TBL] [Abstract][Full Text] [Related]
30. Clinical and pathological outcomes of risk-reducing salpingo-oophorectomy for Japanese women with hereditary breast and ovarian cancer.
Nomura H; Ikki A; Fusegi A; Omi M; Aoki Y; Netsu S; Tanigawa T; Matoda M; Okamoto S; Omatsu K; Nakajima T; Ueki A; Tonooka A; Kanao H
Int J Clin Oncol; 2021 Dec; 26(12):2331-2337. PubMed ID: 34453642
[TBL] [Abstract][Full Text] [Related]
31. Serous tubal intraepithelial carcinoma in a Japanese woman with a deleterious BRCA1 mutation.
Ishikawa H; Kiyokawa T; Utsuno E; Matsushita K; Nomura F; Shozu M
Jpn J Clin Oncol; 2014 Jun; 44(6):597-601. PubMed ID: 24719479
[TBL] [Abstract][Full Text] [Related]
32. High-Grade Serous Carcinoma at Risk-Reducing Salpingo-Oophorectomy in Asymptomatic Carriers of
Stroot IAS; Brouwer J; Bart J; Hollema H; Stommel-Jenner DJ; Wagner MM; van Doorn HC; de Hullu JA; Gaarenstroom KN; Beurden M; van Lonkhuijzen LRCW; Slangen BFM; Zweemer RP; Gómez Garcia EB; Ausems MGEM; Boere IA; van Engelen K; van Asperen CJ; Schmidt MK; Wevers MR; de Bock GH; Mourits MJE;
J Clin Oncol; 2023 May; 41(14):2523-2535. PubMed ID: 36809028
[TBL] [Abstract][Full Text] [Related]
33. Early detection of high-grade tubal serous carcinoma in women at low risk for hereditary breast and ovarian cancer syndrome by systematic examination of fallopian tubes incidentally removed during benign surgery.
Rabban JT; Garg K; Crawford B; Chen LM; Zaloudek CJ
Am J Surg Pathol; 2014 Jun; 38(6):729-42. PubMed ID: 24820399
[TBL] [Abstract][Full Text] [Related]
34. [Early epithelial lesions in prophylactic annexectomies in patients at high risk of ovarian cancer: Report of a series of 93 cases].
Selmes G; Ferron G; Filleron T; Querleu D; Mery E
Gynecol Obstet Fertil; 2015 Oct; 43(10):659-64. PubMed ID: 26433315
[TBL] [Abstract][Full Text] [Related]
35. Quantitative analysis of γ-H2AX and p53 nuclear expression levels in ovarian and fallopian tube epithelium from risk-reducing salpingo-oophorectomies in BRCA1 and BRCA2 mutation carriers.
Staff S; Tolonen T; Laasanen SL; Mecklin JP; Isola J; Mäenpää J
Int J Gynecol Pathol; 2014 May; 33(3):309-16. PubMed ID: 24681744
[TBL] [Abstract][Full Text] [Related]
36. Prophylactic risk-reducing salpingo-oophorectomy in BRCA mutation carriers: what is going on in a region of northern Italy?
Grandi G; Perrone AM; Perrone A; Mandato VD; Comerci G; Sammarini M; Merisio C; Amadori A; Stefanetti M; Martinello R; Facchinetti F; De Iaco P;
Maturitas; 2021 Jan; 143():59-64. PubMed ID: 33308637
[TBL] [Abstract][Full Text] [Related]
37. [Morphologic features of fallopian tubal epithelium in pelvic high-grade serous carcinoma].
Zhao RJ; Wang YY; Li Z; Wu KY; Kong LF; Zheng WX
Zhonghua Bing Li Xue Za Zhi; 2017 Aug; 46(8):542-547. PubMed ID: 28810294
[No Abstract] [Full Text] [Related]
38. Incidence of germline BRCA1/2 mutations in women with tubo-ovarian high-grade serous carcinomas with and without serous tubal intra-epithelial carcinomas.
Dowson CB; Stewart C; O'Sullivan S; Pachter N; Schofield L; Cohen PA
Int J Gynecol Cancer; 2020 Jan; 30(1):94-99. PubMed ID: 31699802
[TBL] [Abstract][Full Text] [Related]
39. Risk-reducing salpingo-oophorectomy (RRSO) in BRCA mutation carriers: experience with a consecutive series of 111 patients using a standardized surgical-pathological protocol.
Powell CB; Chen LM; McLennan J; Crawford B; Zaloudek C; Rabban JT; Moore DH; Ziegler J
Int J Gynecol Cancer; 2011 Jul; 21(5):846-51. PubMed ID: 21670699
[TBL] [Abstract][Full Text] [Related]
40. Value of adjuvant chemotherapy and informed microscopic examination for occult gynecologic cancer detected upon risk-reducing salpingo-oophorectomy after chemotherapy for BRCA1/2-associated breast cancer: a case report.
Kuji S; Kondo H; Ohara T; Deura I; Tozawa-Ono A; Migita O; Kawamoto H; Tsugawa K; Chosokabe M; Koike J; Maeda I; Suzuki N
Jpn J Clin Oncol; 2021 Mar; 51(3):492-497. PubMed ID: 33377156
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
